logo
logo
Sign in

Inhalation and Nasal Spray Generic Drugs Market | Cost Structure Analysis and Forecast to 2033

avatar
Ganesh Shinde
Inhalation and Nasal Spray Generic Drugs Market | Cost Structure Analysis and Forecast to 2033

During the forecast period, the global Inhalation and Nasal Spray Generic Drugs Market is expected to grow at a moderate rate of 8.96%. The market for inhalation and nasal spray generic pharmaceuticals is currently valued at US$ 20.78 billion in 2023. The market for inhalation and nasal spray generic pharmaceuticals is expected to reach a peak of US$ 49.01 by 2033.

The increasing frequency of chronic respiratory illnesses around the world is pushing sales of inhalation and nasal spray generic medications. According to the Global Asthma Report, there are around 330 million people worldwide who suffer from asthma, with this number likely to climb to more than 400 million cases by the year 2025. Increased air pollution, smoking, and tobacco use are the key causes contributing to an increase in the number of persons diagnosed with asthma around the world.

The market for inhalation and nasal spray generic pharmaceuticals is projected to be driven by factors such as the expanding older population and the greater vulnerability of the elderly to persistent respiratory illnesses. According to WHO forecasts, by 2030, one out of every six people on the planet would be 60 years old or older. Furthermore, it is estimated that the global number of such persons will reach 2.1 billion by the year 2050. Furthermore, the Asthma and Allergy Foundation of America projects that by 2020, 7.8% of the population in the United States will be 65 or older and have asthma.

Competitive Landscape

Growth initiatives, such as product innovation, regulatory approval of new products, and mergers and acquisitions, are a primary emphasis of the inhalation and nasal spray generic drugs market leaders. For instance, Cipla Inc. submitted an ANDA for a generic version of Advair Diskus, fluticasone propionate, and salmeterol inhalation powder in May 2020. Phase three trials of the product were successfully completed by the company in April 2020. The following companies are leaders in the global market for generic inhalers and nasal sprays:

  • Mylan N.V.
  • Akorn, Operating Company LLC
  • Cipla Inc.
  • Sandoz International GmBH (Novartis AG)
  • Apotex Inc.
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceuticals Industries Ltd.
  • Beximco Pharmaceuticals Ltd

Read More@ https://www.futuremarketinsights.com/reports/inhalation-and-nasal-spray-generic-drugs-market

Key Segments in the Inhalation and Nasal Spray Generic Drugs Market

Drug Class:

  • Bronchodilators
  • Combination Drugs
  • Corticosteroids
  • Decongestant Sprays
  • Antihistamines
  • Others

Indication:

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Allergic Rhinitis
  • Others

Patient Demographics:

  • Geriatric Patient
  • Adult Patient
  • Paediatric Patient

End-user:

  • Hospitals
  • Homecare
  • Others

Distribution Channel:

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacies


collect
0
avatar
Ganesh Shinde
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more